IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

Cloudera

Datasea Inc

Eros

FuelCell Energy

Contango Oil & Gas

Stage Stores

Although talking about stocks to sell typically elicits anger and negative emotions, this list is all about protecting your interests.

7 Stocks to Sell to Start the New Year Fresh

ArQule

Axsome Therapeutics

Constellation Pharmaceuticals Inc

DURECT

EverBank Financial

Kodiak Sciences Inc

Provention Bio Inc

AVITA Medical Inc

These Were the 10 Best Stocks of 2019

IVERIC bio: Promising Data In GA, Valuation Still Cheap With Multiple Catalysts In 2020

IVERIC bio (ISEE) reported earnings 30 days ago. What's next for the stock?

Why Is IVERIC bio (ISEE) Up 79.1% Since Last Earnings Report?

IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.

IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well

Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2019 Results - Earnings Call Transcript

IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus

Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2019 Results - Earnings Call Transcript

Nova Lifestyle

TheStreet

Market indexes soared Wednesday as investors anticipate an interest rate cut ahead.

4 Ben Graham Net-Net Screener Stocks for All-Time High Market Day

News for IVERIC bio Inc Stock (ISEE)